These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 30826660

  • 1. Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.
    Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S.
    Eur J Cancer; 2019 Apr; 111():82-93. PubMed ID: 30826660
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA MIR21 (miR-21) and PTGS2 Expression in Colorectal Cancer and Patient Survival.
    Mima K, Nishihara R, Yang J, Dou R, Masugi Y, Shi Y, da Silva A, Cao Y, Song M, Nowak J, Gu M, Li W, Morikawa T, Zhang X, Wu K, Baba H, Giovannucci EL, Meyerhardt JA, Chan AT, Fuchs CS, Qian ZR, Ogino S.
    Clin Cancer Res; 2016 Aug 01; 22(15):3841-8. PubMed ID: 26957558
    [Abstract] [Full Text] [Related]

  • 3. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
    Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T, Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S.
    JAMA; 2013 Jun 26; 309(24):2563-71. PubMed ID: 23800934
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
    Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S.
    Clin Cancer Res; 2012 Sep 01; 18(17):4753-63. PubMed ID: 22753589
    [Abstract] [Full Text] [Related]

  • 6. Physical activity, tumor PTGS2 expression, and survival in patients with colorectal cancer.
    Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T, Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S.
    Cancer Epidemiol Biomarkers Prev; 2013 Jun 01; 22(6):1142-52. PubMed ID: 23629521
    [Abstract] [Full Text] [Related]

  • 7. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
    Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M, Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.
    Gut; 2016 Dec 01; 65(12):1973-1980. PubMed ID: 26311717
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. MLH1-deficient Colorectal Carcinoma With Wild-type BRAF and MLH1 Promoter Hypermethylation Harbor KRAS Mutations and Arise From Conventional Adenomas.
    Farchoukh L, Kuan SF, Dudley B, Brand R, Nikiforova M, Pai RK.
    Am J Surg Pathol; 2016 Oct 01; 40(10):1390-9. PubMed ID: 27438990
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.
    Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.
    N Engl J Med; 2012 Oct 25; 367(17):1596-606. PubMed ID: 23094721
    [Abstract] [Full Text] [Related]

  • 13. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.
    Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S.
    J Clin Oncol; 2017 Jun 01; 35(16):1836-1844. PubMed ID: 28406723
    [Abstract] [Full Text] [Related]

  • 14. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF, Dejulius KL, Sanchez JA, Jarrar A, Liu X, Manilich E, Skacel M, Church JM.
    Dis Colon Rectum; 2012 Feb 01; 55(2):128-33. PubMed ID: 22228154
    [Abstract] [Full Text] [Related]

  • 15. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA, Shi Q, Smyrk TC, Thibodeau SN, Dienstmann R, Guinney J, Bot BM, Tejpar S, Delorenzi M, Goldberg RM, Mahoney M, Sargent DJ, Alberts SR.
    Gastroenterology; 2015 Jan 01; 148(1):88-99. PubMed ID: 25305506
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
    Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.
    Am J Surg Pathol; 2012 May 01; 36(5):744-52. PubMed ID: 22314188
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathologic and prognostic associations of KRAS and BRAF mutations in small intestinal adenocarcinoma.
    Jun SY, Kim M, Jin Gu M, Kyung Bae Y, Chang HK, Sun Jung E, Jang KT, Kim J, Yu E, Woon Eom D, Hong SM.
    Mod Pathol; 2016 Apr 01; 29(4):402-15. PubMed ID: 26892442
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.